SNOA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sonoma Pharmaceuticals Inc (SNOA) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows significant pre-market weakness (-20%), bearish technical indicators, and no recent positive news or catalysts to support a rebound. Additionally, the company's financial performance shows declining net income and EPS, which raises concerns about its profitability. Without strong trading signals or positive sentiment, it is better to hold off on investing in SNOA at this time.
The technical indicators are bearish. The MACD is negatively expanding, the RSI is neutral at 29.381, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pre-market price of 1.44, which is below S1 (1.888) and approaching S2 (1.631).
NULL identified. There is no recent news or positive developments to act as a catalyst for the stock.
The stock is down 20% in pre-market trading, indicating significant selling pressure. Additionally, the company's financial performance shows declining net income (-11.75% YoY) and EPS (-23.81% YoY), which raises concerns about its profitability and growth potential.
In Q3 2026, revenue increased by 22.03% YoY to $4,349,000, and gross margin improved to 37.94% (up 6.48% YoY). However, net income dropped to -$819,000 (-11.75% YoY), and EPS fell to -0.48 (-23.81% YoY), reflecting declining profitability despite revenue growth.
No analyst rating or price target data available.
